Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Lee Kalowski currently holds 142,443 shares of Tokai Pharmaceuticals Inc (TKAI), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Lee Kalowski has been a net seller of TKAI stock. They have purchased $0 and sold $3.0M worth of shares.
Lee Kalowski's most recent insider trade was on Jul 16, 2026, when they sold 53,250 shares at $0.00 per share.
Lee Kalowski serves as Executive at Tokai Pharmaceuticals Inc (TKAI). They have executed 39 insider transactions totaling $3.0M over their tenure at the company.
Lee Kalowski holds the position of Executive at Tokai Pharmaceuticals Inc, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 12 years and currently hold a stake valued at $0.
Lee Kalowski has shown a selling trading pattern, with $0 in total purchases and $3.0M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Lee Kalowski was on Jan 19, 2021, when they sold $450.0K worth of BCYC shares. This transaction involved 15,000 shares at $30.00 per share.
Lee Kalowski currently owns 142,443 shares of Tokai Pharmaceuticals Inc (TKAI), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Lee Kalowski's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Lee Kalowski has 39 Form 4 filings on record as an insider at Tokai Pharmaceuticals Inc.
Set alerts for Lee Kalowski and 40,000+ other insiders.